Hims & Hers Health (NYSE:HIMS) Trading 3.2% Higher - What's Next?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price traded up 3.2% during trading on Tuesday . The company traded as high as $44.38 and last traded at $43.33. 30,266,677 shares traded hands during trading, an increase of 36% from the average session volume of 22,255,384 shares. The stock had previously closed at $41.98.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HIMS. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Bank of America increased their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Monday. Finally, Truist Financial set a $45.00 price target on shares of Hims & Hers Health in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $38.31.

Hims & Hers Health Trading Up 12.0%

The company has a market capitalization of $10.38 billion, a P/E ratio of 67.20, a PEG ratio of 1.56 and a beta of 2.09. The stock has a 50 day moving average price of $49.65 and a 200 day moving average price of $39.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the prior year, the firm earned $0.05 EPS. The business's revenue for the quarter was up 110.7% compared to the same quarter last year. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the sale, the chief financial officer now directly owns 124,104 shares in the company, valued at $3,631,283.04. This represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 3,236 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the sale, the insider now directly owns 170,285 shares of the company's stock, valued at $4,728,814.45. This represents a 1.86% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 706,454 shares of company stock worth $35,220,112. 13.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Renaissance Technologies LLC grew its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.